ScholarIQanswers from OpenAlex & ORCID
Michael J. Koren
ResearcherPublications, citations & collaboration network
Michael J. Koren is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael J. Koren have?
ScholarIQindexed works
Michael J. Koren has 155 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael J. Koren have?
ScholarIQcitation count
Michael J. Koren has 16,710 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael J. Koren?
ScholarIQh-index
Michael J. Koren has an h-index of 48 in OpenAlex.
What is the i10-index of Michael J. Koren?
ScholarIQi10-index
Michael J. Koren has an i10-index of 86 in OpenAlex.
What is the OpenAlex record for Michael J. Koren?
ScholarIQopenalex
The OpenAlex for Michael J. Koren is on the source record.
What are the most-cited papers on Michael J. Koren?
ScholarIQmost cited works
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Jane Armitage, Colin Baigent, Elizabeth H Barnes, D. J. Betteridge, Lisa Blackwell, Michael A. Blazing, Louise Bowman, Eugene Braunwald, Robert Byington, Christopher P. Cannon, Michael Clearfield, Helen M. Colhoun, Rory Collins, Björn Dahlöf, Kelly Davies, Barry R. Davis, James A. de Lemos, John R. Downs, Paul N. Durrington, Jonathan Emberson, Bengt Fellström, Marcus Flather, Ian Ford, Maria Grazia Franzosi, Jordan Fulcher, John A. Fuller, Curt D. Furberg, David Gordon, Shinya Goto, Antonio M. Gotto, Heather Halls, Charlie Harper, C. Hawkins, William G. Herrington, G. A. Hitman, Hallvard Holdaas, Lisa Holland, Alan G. Jardine, J. Wouter Jukema, John J.P. Kastelein, Sharon Kean, Anthony Keech, Adrienne Kirby, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Wolfgang Köenig, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Eva Lonn, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Ian C. Marschner, Borislava Mihaylova, Lemuel A. Moyé, Sabina A. Murphy, Haruo Nakamura, Andrew Neil, Connie B. Newman, Rachel O’Connell, Chris J. Packard, Sarah Parish, Terje Pedersen, Richard Peto, Marc A. Pfeffer, Neil Poulter, David Preiss, Christina Reith, Paul M. Ridker, Michele Robertson, Frank M. Sacks, Naveed Sattar, Roland E. Schmieder, Patrick W. Serruys, Peter Sever, John Shaw, Charles L. Shear, John Simes, Peter Sleight, Enti Spata, Luigi Tavazzi, Jonathan A. Tobert, Gianni Tognoni, Andrew Tonkin, Stella Trompet, George Varigos, Christoph Wanner, Hans Wedel, Harvey D. White, John Wikstrand, Lars Wilhelmsen, Kate Wilson, Robin Young, Salim Yusuf, Faı̈ez Zannad
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William O’Riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha‐Lavsky, Jeffrey M. Saland, William G. van’t Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Šimková, Jaap W. Groothoff, David J. Sas, Kristin Meliambro, Jiandong Lu, Marianne T. Sweetser, Pushkal Garg, Akshay Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren, Robert C. Scott, Jae B. Kim, Beat Knüsel, Thomas Liu, Lei Lei, Michael A. Bolognese, Scott M. Wasserman
Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals
Theodore Feldman, Michael J. Koren, William Insull, James M. McKenney, Helmut G. Schrott, Andrew Lewin, Sukrut Shah, Michelle Sidisin, Meehyung Cho, Debra Kush, Yale Mitchel